Suppr超能文献

类风湿关节炎第一年抗TNFα治疗的糖皮质激素节省效应(CORPUS队列)。

Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort).

作者信息

Duquenne Carole, Wendling Daniel, Sibilia Jean, Job-Deslandre Chantal, Guillevin Loic, Benichou Jacques, Flipo René Marc, Guillemin Francis, Saraux Alain

机构信息

Department of Rheumatology, Cavale Blanche University Hospital, Brest, France.

Department of Rheumatology, Besançon University Hospital, and EA 4266, Franche-Comté University, Besançon, France.

出版信息

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):638-646. Epub 2017 May 15.

Abstract

OBJECTIVES

Anti-TNFα agents are indicated in selected patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate and particularly when glucocorticoids are mandatory. We evaluated whether a glucocorticoid-sparing effect occurred during the first year of anti-TNF-α therapy.

METHODS

Between 2007 and 2009, the French multicentre, longitudinal, prospective, observational, population-based CORPUS cohort included biologic-naive patients with inflammatory joint disease. Patients with active RA treated with glucocorticoids were included. Patients who received at least one anti-TNFα injection during follow-up were compared to anti-TNF-α non-users.

RESULTS

Among the 205 patients, 76.1% were women, mean disease duration was 7.7±8.3 years, mean DAS28 was 5.2±1.3, mean follow-up was 13.1±2.8 months, and mean prednisone dose was 9.9±9.6 mg/day. The 75 (36.6%) anti-TNF-α recipients were younger, had a longer RA duration, more often tested positive for rheumatoid factor and anti-citrullinated peptide antibody, more often received previous DMARDs, received a higher methotrexate dosage, had fewer intra-articular glucocorticoid injections at baseline and were more often followed by hospital practitioners than non-recipients. Mean prednisone dosage decreased from 11.8±12.7 to 5.9±9.7 mg/day in recipients and from 8.7±7.1 to 5.0±4.4 mg/day in non-recipients. Prednisone was stopped more often among recipients (21/59, 35.6%) than among non-recipients (16/94, 17.0%) (p=0.01). By multivariate analysis, factors independently associated with lower prednisone requirements were baseline daily prednisone dosage, a CRP >10 mg/l and not to be followed by an office-based practitioner.

CONCLUSIONS

This study showed a significantly higher glucocorticoid discontinuation rate among anti-TNF-α recipients than among non-recipients. However, the glucocorticoid-sparing effect was small and not observed by multivariate analysis.

摘要

目的

抗TNFα药物适用于对甲氨蝶呤反应不充分的特定类风湿关节炎(RA)患者,尤其是在必须使用糖皮质激素的情况下。我们评估了抗TNF-α治疗的第一年是否出现糖皮质激素节省效应。

方法

2007年至2009年期间,法国多中心、纵向、前瞻性、观察性、基于人群的CORPUS队列纳入了初治的炎性关节病患者。纳入接受糖皮质激素治疗的活动性RA患者。将随访期间接受至少一次抗TNFα注射的患者与未使用抗TNF-α的患者进行比较。

结果

205例患者中,76.1%为女性,平均病程为7.7±8.3年,平均DAS28为5.2±1.3,平均随访时间为13.1±2.8个月,平均泼尼松剂量为9.9±9.6mg/天。75例(36.6%)接受抗TNF-α治疗的患者较年轻,RA病程较长,类风湿因子和抗瓜氨酸化肽抗体检测阳性的频率更高,更常接受过先前的改善病情抗风湿药治疗,接受的甲氨蝶呤剂量更高,基线时关节内糖皮质激素注射次数更少,与未接受治疗的患者相比,更常由医院医生随访。接受治疗的患者平均泼尼松剂量从11.8±12.7mg/天降至5.9±9.7mg/天,未接受治疗的患者从8.7±7.1mg/天降至5.0±4.4mg/天。接受治疗的患者中泼尼松停药的频率(21/59,35.6%)高于未接受治疗的患者(16/94,17.0%)(p=0.01)。多因素分析显示,与较低泼尼松需求量独立相关的因素为基线每日泼尼松剂量、CRP>10mg/l以及不由基层医生随访。

结论

本研究显示,接受抗TNF-α治疗的患者中糖皮质激素停药率显著高于未接受治疗的患者。然而,糖皮质激素节省效应较小,多因素分析未观察到。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验